Cytokinetics, Incorporated ( CYTK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytokinetics, Incorporated ( CYTK)

CYTK 64.56

+5.5%

Jan 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	10/13/2011 11:04:30 AM
	of 405

Cytokinetics initiated with a Mkt Outperform at Rodman & Renshaw; tgt $4 8:54 am ET 10/13/2011 - Briefing.com . Rodman & Renshaw initiates CYTK with an Outperform and a $4 tgt saying the co has an advanced program in heart failure partnered with biotech giant Amgen (AMGN) addressing a multi-billion dollar commercial opportunity, as well as a skeletal muscle activator in a Phase 2 program that could attract a partner with multi-hundred mln dollar economics. They recommend that investors build a position in the name ahead of potentially transformative catalysts for the skeletal muscle program in 4Q11.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next